As human stem cell research continues to advance, Institutional Review Boards (IRBs) are increasingly tasked with evaluating studies involving induced pluripotent stem cells (iPSCs), human embryonic stem cells (hESCs), organoids, and embryo models. These research areas create ongoing challenges for IRB reviewers in determining when Stem Cell Research Oversight (SCRO) review is required and what level of SCRO involvement is appropriate.
This session will provide guidance to navigate and apply ISSCR Categories 1A and 1B to distinguish routine research that requires SCRO acknowledgment from activities that warrant full SCRO committee review. Presenters will clarify how 45 CFR 46, ISSCR guidance, and relevant federal and state policies intersect in the review of stem cell research involving human subjects.
Eligible for 1.5 CIP recertification credit.